Shares of Repros Therapeutics Inc. (NASDAQ: RPRX) climbed in Thursday’s session after the company announced results from its mid-stage study for women with moderate to severe confirmed endometriosis. Overall, the subjects’ menstrual pain decreased significantly over the course of the study.
A key takeaway from this study was that with these results, the company is making plans with the U.S. Food and Drug Administration (FDA) to further discuss late-stage development and Phase 3 studies.
As anticipated, 70% of subjects treated with Proellex became amenorrheic (missing menstrual periods). The induction of amenorrhea was associated with a substantial reduction in reported pain and subsequent reduction in analgesic use. Responses were similar across the two doses of Proellex.
Also as a result, total pain medication use decreased 56% and non-prescription pain medication use decreased by 74% in subjects treated with Proellex.
Despite evidence of a placebo response, subjects treated with Proellex had a statistically significant greater reduction in menstrual pain compared to the 37.5% change from baseline achieved with placebo. Although non-menstrual pelvic pain was also reduced with treatment, a difference between treatment groups could not be detected.
For some background on Repros Therapeutics: The firm focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Excluding Thursday’s move, Repros has outperformed the broad markets, with the stock up 57% year to date. Over the past 52 weeks, the stock is actually down 74%.
Shares of Repros were last seen up 14% at $2.17 on Thursday, with a consensus analyst price target of $3.50 and a 52-week trading range of $0.80 to $8.96.